The Pharma Data

DECEMBER 17, 2020

(NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. “The investigational cocktail is now available to indicated high-risk U.S.

Hospitals 52

Hospitals Production Clinical Trials Virus 52

The Pharma Data

OCTOBER 23, 2020

A solidarity clinical trial “is one of the largest international randomized trials for Covid-19 treatments, enrolling almost 12,000 patients in 500 hospital sites in over 30 countries”, according to the World Health Organization (WHO), which launched the trail with a number of partners. Overall, in-hospital mortality was 12.9

Trials 52

Trials Immune Response Hospitals Clinical Trials 52

The Pharma Data

SEPTEMBER 25, 2020

The data demonstrate that a single dose of JNJ-78436735 induced a strong neutralizing antibody response in nearly all participants aged 18 years and older and was generally well-tolerated. Immune responses were similar across the age groups studied, including older adults. Immune Response Data.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

Broad Institute

OCTOBER 4, 2023

This is an unprecedented opportunity to evaluate how immune responses work,” said Robert Manguso , who is co-senior author on the study, an associate member at the Broad, and an assistant professor at the Massachusetts General Hospital Center for Cancer Research and Harvard Medical School.

Small Molecule 128

Small Molecule Clinical Trials Trials Engineering 128

The Pharma Data

NOVEMBER 18, 2020

.” Ming-Tain Lai, PhD, Chief Scientific Officer at OBI Pharma stated, “In the trial, OBI-833 demonstrated a favorable safety profile and generated detectable anti-Globo H IgM/IgG responses. Department of Internal Medicine, Tri-Service General Hospital, Taipei, Taiwan. ” Presentation number: 397P / Poster: ID 680.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

The Pharma Data

JUNE 26, 2021

In line with our global leadership and our 7 0-year history of pro tecting people with influenza v accine s , w e will always focus on developing product s that demonstrate protection beyond flu , as we believe it is critical to demonstrate protecting patients from hospitalizations due to cardiovascular events and pneumonia.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

OCTOBER 6, 2021

Fluzone High-Dose is the only influenza vaccine that has demonstrated reductions in influenza-related complications such as hospitalizations due to cardiovascular events and pneumonia, over 10 consecutive seasons in more than 34 million people aged 65 and older 1 , 2 , 3. Full results of the study will be published later this year.

Vaccine 52

Vaccine Licensing Licensing Immune Response 52

The Pharma Data

JUNE 17, 2022

In a Phase 2/3 clinical trial, the Pfizer-BioNTech COVID-19 Vaccine elicited a strong immune response in this age group Three 3-µg doses had favorable safety profile similar to placebo in young children ages 6 months through 4 years in Phase 2/3 clinical trial Pfizer-BioNTech COVID-19 Vaccine now authorized in the U.S.

Vaccine 52

Vaccine FDA Clinical Trials Immune Response 52

The Pharma Data

FEBRUARY 23, 2022

. * In the VAT08 Phase 3 primary series trial, two doses of the Sanofi-GSK vaccine in seronegative populations demonstrated: * 100% efficacy against severe COVID-19 disease and hospitalizations * 75% efficacy against moderate or severe COVID-19 disease * 57.9% Favorable safety profile following both primary series and booster vaccinations.

Vaccine 52

Vaccine Virus Trials Immune Response 52

NIH Director's Blog: Drug Development

OCTOBER 27, 2020

While further study is needed to understand all the details and their implications, it suggests that this interaction may alter important aspects of the human immune response, including blocking interferon signals that are crucial for sounding the alarm to prevent serious illness. And the results were quite striking.

Drug Development 52

Drug Development Drugs Virus Science 52

The Pharma Data

OCTOBER 28, 2020

REGN-COV2 significantly reduced viral load and patient medical visits (hospitalizations, emergency room, urgent care visits and/or physician office/telemedicine visits). Clinical results in the overall population (n=799): On the key clinical endpoint, treatment with REGN-COV2 reduced COVID-19 related medical visits by 57% through day 29 (2.8%

Virus 40

Virus Trials Clinical Trials Production 40

The Pharma Data

DECEMBER 23, 2020

All 38 subjects who were evaluable for immunogenicity had balanced cellular and humoral immune responses following the second dose of INO-4800. The lead Principal Investigator for the INNOVATE trial is Dr. Pablo Tebas , Professor of Medicine at the Hospital of the University of Pennsylvania.

DNA 40

DNA Vaccine Clinical Trials Immune Response 40

The Pharma Data

FEBRUARY 18, 2022

“For clinicians treating patients with this serious, chronic disease, results from the True North extension study provide an understanding of long-term therapeutic outcomes and help to identify an appropriate treatment approach for their patients with ulcerative colitis,” said Silvio Danese, M.D., About Ulcerative Colitis.

Clinical Trials 40

Clinical Trials Treatment Immune Response Disease 40

The Pharma Data

NOVEMBER 10, 2020

We believe the scientific rationale for oral treatment with Foralumab is logical to facilitate topical action at the inflamed sites in the gastrointestinal tract. Additionally, oral capsules provide the convenience of home use, and increase patient compliance by eliminating the need for infusions in a clinic or hospital setting.

Clinical Trials 40

Clinical Trials Science Disease Trials 40

The Pharma Data

SEPTEMBER 5, 2021

1 Tezepelumab is a potential first-in-class treatment that acts at the top of the inflammatory cascade by targeting thymic stromal lymphopoietin (TSLP), an epithelial cytokine, and has the potential to treat a broad population of patients with severe asthma. 7,8,9 Uncontrolled asthma occurs when symptoms persist despite treatment.

Trials 52

Trials Clinical Trials Therapies Treatment 52

The Pharma Data

NOVEMBER 9, 2020

Specifically, tezepelumab targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic and other types of airway inflammation associated with severe asthma. 6,7 Approximately 10% of asthma patients have severe asthma.

Trials 52

Trials Production Clinical Trials Government 52

Broad Institute

DECEMBER 6, 2023

Using single-cell RNA sequencing to analyze gene expression in individual cells, the researchers have found how 86 major cytokines affect 17 immune cell types in mice. NH: This is the first single-cell resolution dictionary of each major immune cell type responding to each major cytokine in vivo at an unprecedented scale.

Immune Response 138

Immune Response RNA Disease Medical Schools 138

Broad Institute

FEBRUARY 26, 2025

In a new study in Nature , the researchers found four gene expression programs sets of genes with coordinated activity that either suppress the immune system or make it more active. Clustering cells As a pathology resident, Miller watched treatment after treatment fail in patients with gliomas.

Immune Response 132

Immune Response Treatment RNA Clinical Trials 132

Broad Institute

MARCH 20, 2024

doi: 10.1038/s41590-024-01792-2 (2024) Scientists used a microscope to visualize an immunity hub (yellow and green) in human lung tumor tissue (blue). They analyzed individual immune cells from human lung tumor samples taken from 68 people before they were treated with PD-1 inhibitors. Nature Immunology.

Immune Response 131

Immune Response Hospitals Research Treatment 131

The Pharma Data

DECEMBER 29, 2020

29, 2020 /PRNewswire/ — Phase 3 program in hospitalized patients to continue based on passing futility analysis on ability to reduce incidence of death or mechanical ventilation. As in earlier outpatient trial, immune status when patients entered the trial was a strong predictor of viral load and clinical outcomes.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

PLOS: DNA Science

OCTOBER 3, 2024

“BCG” is the “treatment” vaccine’s technical name, for Mycobacterium bovis Bacillus Calmette-Guérin. Then researchers test treatments on the zAvatars. This takes just a few days, compared to the weeks or months required to test treatments in mice. And every so often, tumors shrank.

Vaccine 52

Vaccine Immune Response DNA Treatment 52

PLOS: DNA Science

SEPTEMBER 5, 2024

Diagnosis began to shift from a body-part basis to a molecular one, which I wrote about in “Mutation and location important in cancer treatment” for The Lancet in 2015. This removes the cancer’s blocking of the immune response, so that T cells can fight the cancer.

Treatment 68

Treatment FDA Approval DNA Small Molecule 68

The Pharma Data

JANUARY 25, 2021

In a surprise move, Merck announced that it is giving up on its two coronavirus vaccine candidates after seeing a subpar immune response and shifting its focus to a pair of investigational coronavirus treatments. MK-7110, previously known as CD24Fc, is a recombinant fusion protein that controls the body’s inflammatory response.

Vaccine 52

Vaccine Immune Response Trials Clinical Trials 52

The Pharma Data

APRIL 16, 2021

Approval based on Phase 3 CheckMate -9ER trial results showing Opdivo in combination with Cabometyx significantly improved overall survival and doubled median progression-free survival and objective response rates compared to sunitinib. professor of medicine and urology department head, Jena University Hospital.

Treatment 52

Treatment Trials Clinical Trials Immune Response 52

The Pharma Data

NOVEMBER 20, 2020

The clinical evidence from Regeneron’s outpatient trial suggests that monoclonal antibodies such as casirivimab and imdevimab have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load. Department of Health and Human Services.

Therapies 52

Therapies FDA Clinical Trials Hospitals 52

The Pharma Data

SEPTEMBER 17, 2020

The Elecsys Anti-SARS-CoV-2 serology test can be used to quantitatively measure antibodies in people who have been exposed to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and can play an important part in characterising a vaccine-induced immune response.

Vaccine 52

Vaccine Virus Clinical Trials Immune Response 52

Broad Institute

AUGUST 7, 2023

Now, a team of MIT, Massachusetts General Hospital (MGH), Broad Institute of MIT and Harvard, and Harvard Medical School (HMS) researchers has discovered how STING activates those two pathways. Food and Drug Administration has not approved any STING agonist thus far, although multiple clinical trials are currently underway.

Regulations 91

Regulations Clinical Trials Engineering Science 91

The Pharma Data

OCTOBER 18, 2020

Food and Drug Administration (FDA) to begin the Phase 2 portion of its Phase 2/3 clinical study of its investigational drug, EB05, for the treatment of hospitalized COVID-19 patients. Should the antibody treatment demonstrate promising results at the Phase 2 readout, the company plans to continue with a pivotal Phase 3 study.

Immune Response 40

Immune Response Hospitals Treatment Virus 40

The Pharma Data

APRIL 8, 2022

Now, new research from the Wyss Institute at Harvard University has revealed that this constant pattern of stretching and relaxing does even more – it generates immune responses against invading viruses. a Wyss Technology Development Fellow at the Institute. ” The results are published today in Nature Communications. .

Virus 52

Virus Immune Response Disease Clinical Trials 52

The Pharma Data

JANUARY 3, 2021

Anecdotal feedback from Foralumab-treated patients was positive and suggests that the treatment was well-tolerated. This trial is the first to evaluate nasally administered Foralumab to improve the immune system’s fight against coronaviruses. NEW YORK and LONDON, Jan. NEW YORK and LONDON, Jan.

Clinical Trials 40

Clinical Trials Science Treatment Trials 40

The Pharma Data

DECEMBER 9, 2020

In the new study, researchers found that among COVID patients at their safety-net hospital, neurological complications ran the gamut. Safety-net hospitals are obligated, by mandate or mission, to treat people regardless of their ability to pay. The patient improved after treatment with anti-inflammatory corticosteroids.

Hospitals 52

Hospitals Doctors Immune Response Virus 52

The Pharma Data

OCTOBER 28, 2020

We are pursuing an accelerated approval pathway for remestemcel-L in the treatment of children with SR-aGVHD, and a parallel approval pathway for COVID-19 ARDS if the randomized controlled Phase 3 trial is positive.”. Trial enrollment across more than 20 hospitals in the United States has surpassed 50% of the total 300 patient target.

Treatment 40

Treatment Trials Disease Production 40

The Pharma Data

NOVEMBER 21, 2020

21, 2020 /PRNewswire/ — First treatment of any kind to have prospectively confirmed and statistically significant anti-viral activity against SARS-CoV-2. This benefit was greatest in patients most at risk for poor outcomes due to high viral load, ineffective immune response at baseline or pre-existing risk factors.

FDA 40

FDA Clinical Trials Hospitals Production 40

The Pharma Data

MARCH 3, 2022

million outpatient visits and 58,000 hospitalizations occur each year among children younger than five years old. RSV infections account for approximately 177,000 hospitalizations and 14,000 deaths each year. Burden of RSV RSV is a contagious virus and a common cause of respiratory illness. 8,9 For older adults in the U.S.,

Virus 52

Virus Vaccine Clinical Trials Trials 52

The Pharma Data

JULY 8, 2021

Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) and granted Priority Review for tezepelumab in the treatment of asthma. Many patients with severe asthma have an inadequate response to currently available biologics and oral corticosteroids and thus fail to achieve asthma control.(2,6,9)

FDA 52

FDA Trials Therapies Treatment 52

Codon

FEBRUARY 13, 2024

doi: 10.2210/rcsb_pdb/goodsell-gallery-048 The Virus that Cures It’s been over 25 years since the science magazine Discover first ran an extraordinary article about how a long-forgotten medical treatment, used in the former Soviet country of Georgia, could save us from the growing threat of untreatable, drug-resistant infections.

Therapies 131

Therapies Virus DNA Clinical Trials 131

The Pharma Data

AUGUST 11, 2020

We look forward to engaging health authorities worldwide with the goal of bringing this immunotherapy-based treatment option to patients as soon as possible.”. All patients continued treatment for two years or until disease progression, unacceptable toxicity or withdrawal of consent. Waxman, M.D., About Esophageal Cancer.

Treatment 52

Treatment Trials Therapies Clinical Trials 52